Artificial Intelligence In Drug Discovery Market Size Is Anticipated To Reach USD 9.1 Billion By 2030

 San Francisco, 27 Aug 2024: The Report Artificial Intelligence In Drug Discovery Market Size, Share & Trends Analysis Report By Therapeutic Space (Oncology, Neurodegenerative Diseases), By Application, By Region, And Segment Forecasts, 2024 - 2030

The global artificial intelligence in drug discovery market size is estimated at USD 9.1 billion in 2030, and is expected to expand at a CAGR of 29.7% from 2024 to 2030. It is expected to expand at a CAGR of 29.6% from 2023 to 2030. The pandemic has made the adoption of AI more widespread in the pharma industry. AI and its related platforms aim to enhance medical imaging and diagnostics, management of chronic diseases, and drug designing. The overall human hours spent would be far more in comparison to the AI system scanning the same data, which reduces overall cost and is a more feasible approach.

The drug optimization and repurposing application segment held the largest revenue share in 2022. AI platforms help in the identification of target proteins for drugs to determine adverse events and possible side effects the drug can have. Drug molecules can be repurposed to make them more effective and with minimum side effects. Portfolio drugs for a company can be altered and studied using AI platforms at a much faster pace so as to hasten new drug development.

The oncology therapeutic area segment accounted for the largest revenue share in 2022. The majority of the pharmaceutical companies are pairing up with AI start-ups to optimize their cancer research, which is still an unchartered territory and there is a lot to be discovered. AI systems can identify cancer much earlier than a regular scan would indicate to even a thoroughly trained radiologist. This, in turn, can increase life expectancy and can also help identify markers to be studied for cancer research and drug development. Patients can be prescribed treatments suited to their genetic composition.

North America dominated the market in 2022. Many tech companies are now investing their money and efforts toward the use of AI in pharmaceutical companies. Companies like IBM, Microsoft, and other tech giants have formed collaborations with research institutes for faster drug development and clinical trials for multiple indications. Developing countries are also finding cost-effective measures to implement AI technology for their drug development and disease understanding.

Access Research Report of Artificial Intelligence in Drug Discovery Market @ https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-drug-discovery-market

Artificial Intelligence In Drug Discovery Market Report Highlights

• The drug optimization and repurposing application segment dominated the market and accounted for a revenue share of over 53.9% in 2022
• By therapeutic area, the oncology segment held the largest revenue share of over 23.4% in 2022. The infectious diseases segment is expected to register the fastest growth rate during the forecast period
• Asia Pacific is expected to expand at the fastest CAGR from 2023 to 2030. This can be attributed to the increasing adoption of AI among the developing countries in this region as a means to understand diseases and aid drug discovery
• North America led the market and accounted for a revenue share of over 58.0% in 2022. The U.S. is significantly contributing to the regional market growth as the country has been the forerunner in the artificial intelligence technology

Artificial Intelligence In Drug Discovery Market Report Scope

Report Attribute	Details
The market size value in 2024	USD 1.9 billion
The revenue forecast in 2030	USD 9.1 billion
Growth Rate	CAGR of 29.7% from 2024 to 2030
Historical data	2018 - 2022
Forecast period	2024 - 2030

Key Players in Artificial Intelligence In Drug Discovery Market

• IBM
• Exscientia
• Insilico Medicine
• GNS Healthcare (In January 2023, the company Rebranded as Aitia)
• Google (DeepMind)
• BenevolentAI
• BioSymetrics, Inc.
• Berg Health (In January 2023, Berg Health acquired by BPGbio Inc.)
• Atomwise Inc.
• insitro
• CYCLICA (In May 2023, CYCLICA acquired by Recursion)

Access Press Release of Artificial Intelligence in Drug Discovery Market @ https://www.grandviewresearch.com/press-release/global-artificial-intelligence-drug-discovery-market

About Grand View Research

Grand View Research is an India & U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

For More Information: https://www.grandviewresearch.com/horizon